These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 22872786)

  • 41. Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.
    Dold L; Nielsen MJ; Praktiknjo M; Schwarze-Zander C; Boesecke C; Schierwagen R; Mohr R; Wasmuth JC; Jansen C; Bischoff J; Rockstroh JK; Karsdal MA; Spengler U; Trebicka J; Leeming DJ
    PLoS One; 2019; 14(7):e0219526. PubMed ID: 31295293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis.
    Rubiś P; Wiśniowska-Smiałek S; Wypasek E; Rudnicka-Sosin L; Hlawaty M; Leśniak-Sobelga A; Kostkiewicz M; Podolec P
    Cytokine; 2017 Aug; 96():217-227. PubMed ID: 28460256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Partial hepatectomy-induced regeneration accelerates reversion of liver fibrosis involving participation of hepatic stellate cells.
    Suárez-Cuenca JA; Chagoya de Sánchez V; Aranda-Fraustro A; Sánchez-Sevilla L; Martínez-Pérez L; Hernández-Muñoz R
    Exp Biol Med (Maywood); 2008 Jul; 233(7):827-39. PubMed ID: 18445764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hepatic fibrosis: physiopathology and biological diagnosis].
    Housset C; Guéchot J
    Pathol Biol (Paris); 1999 Nov; 47(9):886-94. PubMed ID: 10609268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis.
    Parés A; Deulofeu R; Giménez A; Caballería L; Bruguera M; Caballería J; Ballesta AM; Rodés J
    Hepatology; 1996 Dec; 24(6):1399-403. PubMed ID: 8938169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Mechanism Responsible for Fibronectin-controlled Alterations in Matrix Stiffness in Advanced Chronic Liver Fibrogenesis.
    Iwasaki A; Sakai K; Moriya K; Sasaki T; Keene DR; Akhtar R; Miyazono T; Yasumura S; Watanabe M; Morishita S; Sakai T
    J Biol Chem; 2016 Jan; 291(1):72-88. PubMed ID: 26553870
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genesis of hepatic fibrosis and its biochemical markers.
    Das SK; Vasudevan DM
    Scand J Clin Lab Invest; 2008; 68(4):260-9. PubMed ID: 18609066
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Hsu WH; Liao SC; Chyan YJ; Huang KW; Hsu SL; Chen YC; Siu ML; Chang CC; Chung YS; Huang CF
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.
    Saitou Y; Shiraki K; Yamanaka Y; Yamaguchi Y; Kawakita T; Yamamoto N; Sugimoto K; Murata K; Nakano T
    World J Gastroenterol; 2005 Jan; 11(4):476-81. PubMed ID: 15641129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Assessment of hepatic fibrosis].
    Solís-Herruzo JA; Muñoz Yagüe MT
    Rev Esp Enferm Dig; 1992 Feb; 81(2):121-8. PubMed ID: 1567703
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathobiology of liver fibrosis: a translational success story.
    Lee YA; Wallace MC; Friedman SL
    Gut; 2015 May; 64(5):830-41. PubMed ID: 25681399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats.
    Hu YB; Li DG; Lu HM
    J Gene Med; 2007 Mar; 9(3):217-29. PubMed ID: 17351970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated serum aminoterminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis.
    Gerling B; Becker M; Waldschmidt J; Rehmann M; Schuppan D
    J Hepatol; 1996 Jul; 25(1):79-84. PubMed ID: 8836905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease.
    Pereira TN; Lewindon PJ; Smith JL; Murphy TL; Lincoln DJ; Shepherd RW; Ramm GA
    J Hepatol; 2004 Oct; 41(4):576-83. PubMed ID: 15464237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver fibrosis: from the bench to clinical targets.
    Pinzani M; Rombouts K
    Dig Liver Dis; 2004 Apr; 36(4):231-42. PubMed ID: 15115333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Liver fibrosis: pathophysiology, diagnosis and treatment].
    Pár A; Pár G
    Orv Hetil; 2005 Jan; 146(1):3-13. PubMed ID: 15715367
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers.
    Agbim U; Asrani SK
    Expert Rev Gastroenterol Hepatol; 2019 Apr; 13(4):361-374. PubMed ID: 30791772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Collagen and tissue turnover as a function of age: Implications for fibrosis.
    Karsdal MA; Genovese F; Madsen EA; Manon-Jensen T; Schuppan D
    J Hepatol; 2016 Jan; 64(1):103-9. PubMed ID: 26307398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Utility of Biomarkers of Liver Fibrosis.
    Patel K; Rockey DC
    Gastroenterol Hepatol (N Y); 2006 Jan; 2(1):48-57. PubMed ID: 28210197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey.
    Gressner AM; Gao CF; Gressner OA
    World J Gastroenterol; 2009 May; 15(20):2433-40. PubMed ID: 19468990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.